clinical trial · NCT03767348
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune, Inc.·phase2·active not recruiting·n = 340
Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)Cutaneous MelanomaRP1nivolumab
brief summary
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).
started
Sep 20, 2017
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Feb 13, 2026
official title
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol